Pharmacokinetics, tissue distribution and plasma protein binding study of SM-1, a novel PAC-1 derivative.
Absorption, Physicochemical
Animals
Azepines
/ chemistry
Biological Availability
Blood Proteins
/ metabolism
Brain
/ metabolism
Chromatography, High Pressure Liquid
/ instrumentation
Dogs
Drug Screening Assays, Antitumor
/ instrumentation
Female
Humans
Hydrazones
/ chemistry
Lung
/ metabolism
Male
Muscles
/ metabolism
Piperazines
/ chemistry
Protein Binding
Rats
Rats, Sprague-Dawley
Reproducibility of Results
Tandem Mass Spectrometry
/ instrumentation
Tissue Distribution
Anti-tumour drugs
Pharmacokinetics
Plasma protein binding
SM-1
Tissue distribution
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
30 Jan 2019
30 Jan 2019
Historique:
received:
03
06
2018
revised:
19
09
2018
accepted:
22
09
2018
pubmed:
3
10
2018
medline:
29
1
2019
entrez:
2
10
2018
Statut:
ppublish
Résumé
As a PAC-1 derivative, SM-1 exhibts a promising antitumour property. To better understand the relationship between the drug concentrations and pharmacological effects, both liquid chromatography coupled with tandem mass spectrometry and high performance liquid chromatography methods were developed and validated in the work. Those methods were then applied to the pharmacokinetics (PK), tissue distribution and plasma protein binding (PPB) studies of SM-1. As a results, the proposed methods were demonstrated to be accurate, precise and stable for the analysis of the SM-1 in plasma and tissue samples. Meanwhile, the PK parameters of SM-1 showed that SM-1 had good PK properties. SM-1 had good absorption in the body, with 59.01% of the absolute bioavailability in rats and 55.63% of that in dogs. SM-1 rapidly distributed to all tissues, with the highest distribution in the lung and less in the brain and muscle. The PPB rates in rat plasma, dog plasma, and human plasma were 91.1%, 91.2%, and 90.7%, respectively. These good PK properties will contribute SM-1 to be a promising anti-tumour candidate. These results also provide insights into the further pharmacological investigation of SM-1.
Identifiants
pubmed: 30273837
pii: S0731-7085(18)31314-1
doi: 10.1016/j.jpba.2018.09.043
pii:
doi:
Substances chimiques
(4-benzylpiperazin-1-yl)acetic acid (3-allyl-2-hydroxybenzylidene)hydrazine
0
Azepines
0
Blood Proteins
0
Hydrazones
0
Piperazines
0
SM-1 compound
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-23Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.